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Clinical Trials:What ExactlyAreWe Measuring?
Carolyn Charman, Colette Chambers, and HywelWilliams
Center of Evidence-Based Dermatology, Queen’s Medical Center, University Hospital, Nottingham, UK
Well-designed clinical trials are a fundamental aspect of
evidence-based medicine. Such trials are dependent on
the use of valid, reliable, and relevant outcome mea-
sures.Wide variation in outcome methodology can have
important detrimental e¡ects on the correct interpreta-
tion and comparison of results. The objective of this
study was to describe the variation in outcome metho-
dology in randomized controlled trials of therapeutic
interventions for atopic dermatitis published between
January 1994 and December 2001. Of the 93 eligible ran-
domized controlled trials identi¢ed using a systematic
electronic database search strategy, 85 (91%) incorpo-
rated an objective measurement of clinical signs. Only
23 (27%) of these trials used a published severity scale,
however. The remainder used either modi¢ed versions
of published scales (14%) or unnamed scales with no
data on validity or reliability (59%), although unpub-
lished scales were used signi¢cantly less frequently
over the last 2 y compared to previously (21% vs 74%,
po0.01). There was lack of consensus on which clinical
features best re£ect disease severity, with 31 di¡erent de-
scriptions of clinical signs being used across all scoring
systems. Fifty-six di¡erent ‘‘objective’’ clinical scales
were identi¢ed. Patient symptoms were recorded in 80
trials (86%) and disease extent in 62 trials (67%). Qual-
ity of life was measured in only three trials (3%). This
wide variation in outcome methodology is hindering
evidence-based practice, and the widespread use of un-
validated outcome measures is a potential source of bias
and inaccuracy. More emphasis should be placed on
measuring things that are important to patients such as
symptoms and quality of life. Key words: index/outcome
measures/severity score. J Invest Dermatol 120:932 ^941, 2003
A
topic dermatitis is a distressing in£ammatory skin
disease a¡ecting between 0.3% and 20% of children
worldwide (Williams et al, 1999). In the UK the
disease accounts for 10%^20% of all referrals to
dermatologists and about 30% of dermatologic con-
sultations in general practice, with an estimated annual cost of
d47 million for preschool children alone (Emerson et al, 2001).
Disease prevalence has steadily increased over the last 30 y (Diep-
gen, 2000), signi¢cantly impacting health care resources world-
wide, and resulting in a growing ¢eld of atopic dermatitis
research. As more and more emphasis is being placed on the
results of randomized controlled clinical trials (RCTs) to inform
clinical practice, the use of valid and clinically meaningful patient
outcome measures is becoming increasingly important.
Given the importance of atopic dermatitis as a health issue, it is
surprising that so little e¡ort has been expended by clinicians, re-
searchers, regulatory authorities, and drug companies in trying to
standardize scoring systems for measuring disease severity in the
clinical trial setting. Poor standardization and lack of proven
validity not only hinders the comparison of results and produc-
tion of systematic reviews but also prohibits the meaningful in-
terpretation of individual studies. The atopic dermatitis literature
is characterized by a confusing array of severity indices. Even
many of the 13 or so named published scoring systems have
little available data on validity or reliability testing (Charman
andWilliams, 2000).
The aim of this study was to assess the extent of heterogeneity
in outcome measures used for recording atopic dermatitis severity
in recent RCTs, and to establish which measures were being most
widely used by researchers and clinicians.
METHODS
A systematic electronic search strategy was used to retrieve all RCTs of
therapies for atopic dermatitis published between January 1994 and Decem-
ber 2001. The following electronic databases were searched: Medline, EM-
BASE, The Cochrane Controlled Trials Register, and the Cochrane Skin
Group Specialized Trials Register.The Cochrane Collaboration highly sen-
sitive electronic search string was used to search Medline (OVID). The
search string developed by the British Medical Journal Publishing Group
for its Clinical Evidence series (Barton, 2001) was used to search EMBASE
(OVID). The following disease terms were used; eczema, atopic dermatitis,
atopic eczema, infantile eczema, childhood eczema, neurodermatitis, and
Besnier’s prurigo. Only RCTs of therapeutic agents used in the treatment
of people with atopic dermatitis (as diagnosed by a physician) of any
age were considered for inclusion. Studies that only reported changes in
blood tests or cellular mechanisms were excluded. Studies that included
other forms of eczema in the analysis or those that did not specify atopic
dermatitis were also excluded from the analysis. Studies published in
non-English languages for which a published English translation was not
available were excluded.
RESULTS
A total of 93 RCTs were identi¢ed (Table I). Topical and oral
corticosteroids were the most frequently studied therapeutic
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agent (16 trials), followed by antibacterial and antifungal prepara-
tions (nine trials), essential fatty acid supplementation, e.g., eve-
ning primrose oil, ¢sh oil, and borage oil (seven trials), and
dietary manipulation (seven trials). Outcome measures included
assessments of physical features of the disease visible to the physi-
cian (clinical signs), subjective indicators perceived by the patient
(symptoms), estimations of body surface area involvement, and
overall impressions of disease severity (global scales). The scores
on measurement scales of individual parameters were frequently
combined to form an overall severity index.
Clinical signs Of the 93 trials identi¢ed, 85 (91%) included an
assessment of clinical signs (Table II). Within these 85 RCTs, a
total of 31 di¡erent clinical sign descriptions had been used to
measure disease severity. Fifty-six di¡erent objective scoring
systems were identi¢ed, using 51 di¡erent combinations of
clinical signs. Distinct clinical signs were scored together in
some trials, e.g., papulation/erosion/scaling or scaling/crusting
(Table II). The total number of signs used in each index ranged
from 1 to 10, and the grading used for measuring individual
clinical signs ranged from 02 to 0100 where speci¢ed. No
sign was common to all studies. Erythema was assessed in 80 of
85 trials (94%), licheni¢cation in 71 of 85 trials (84%), and
excoriations in 54 of 85 trials (64%), with the remaining signs
being recorded in less than 35% of trials.
Published severity indices Only 23 of the 85 trials (27%) employed
a previously published named scoring system.The SCORAD in-
dex (European Task Force on Atopic Dermatitis, 1993) was the
most frequently employed system (11 trials) followed by the
Eczema Area and Severity Index (EASI) (three trials) (Hani¢n
et al, 2001b), Costa’s Simple Scoring System (three trials) (Costa
et al, 1989), the Six Area Six Sign Atopic Dermatitis index (SAS-
SAD) (two trials) (Berth-Jones, 1996), the Atopic Dermatitis
Severity Index (ADSI) (one trial) (Van Leent et al, 1998), the Ato-
pic Dermatitis Area and Severity Index (ADASI) (one trial) (Bah-
mer and Schubert, 1991), the Total Body Severity Assessment
(TBSA) (one trial) (Van Joost et al, 1992), and the Dry Skin Area
and Severity Index (DASI) (Serup, 1995) (one trial). The latter
index was not designed speci¢cally for measuring atopic
dermatitis severity.
Modi¢ed published severity indices A further 12 trials (14%) used a
modi¢ed version of a published index, based on the SCORAD
index (four trials), SASSAD index (three trials), Costa’s Simple
Scoring System (two trials), EASI (two trials), or the TBSA (one
trial). Modi¢ed scoring systems were sometimes employed for a
clear reason, e.g., when only half the body was treated (Tzaneva
et al, 2001), or when the head and neck area was not included
(Luger et al, 2001). In the majority of trials, however, modi¢ca-
tions were made for no clear reason, and included substituting
clinical signs or using di¡erent gradings from those in the origi-
nal tested scoring system.
Unpublished severity indices The remaining 50 trials (59%) used a
variety of unnamed ‘‘objective’’ scoring systems with no published
data on validity and reliability testing, using 36 di¡erent combi-
nations of clinical signs in total.
Table I. Treatments for atopic dermatitis studied in RCTs from January 1994 to December 2001
Therapy under investigation Number of RCTs References
Corticosteroids 16 Marchesi et al, 1994; Stalder et al, 1994; Bleehen et al, 1995; Jorizzo et al, 1995; Koopmans et al, 1995;
La Rosa et al, 1995; Hiratsuka et al, 1996; Lebwohl, 1996; 1999; Reidhav and Svensson, 1996;
Sears et al, 1997; Traulsen, 1997; Maloney et al, 1998;Wolkerstorfer et al, 1998;
Van Der Meer et al, 1999; Cato et al, 2001
Antimicrobials 9 Korting et al, 1994; Broberg and Faergemann, 1995; Harper, 1995; Holland et al, 1995;
Poyner and Dass, 1996; Ramsay et al, 1996; Ewing et al, 1998; Breneman et al, 2000; Lintu et al, 2001
Essential fatty acids 7 Biagi et al, 1994; Humphreys et al, 1994; Soyland et al, 1994; Hederos and Berg, 1996;
Valsecchi et al, 1996; Gimenez-Arnau et al, 1997; Henz et al, 1999
Dietary manipulation 7 Isolauri et al, 1995; 2000; Mabin et al, 1995a; Ventura et al, 1996; Majamaa and Isolauri, 1997;
Lever et al, 1998; Niggemann et al, 2001
Cyclosporin 6 Munro et al, 1994;Van Joost et al, 1994; Zonneveld et al, 1996; Zurbriggen et al, 1999;
Czech et al, 2000; Harper et al, 2000
Anti-house dust mite measures 6 Galli et al, 1994; Tan et al, 1996; Friedmann and Tan, 1998; Ricci et al, 2000;
Gutgesell et al, 2001; Holm et al, 2001
Tacrolimus 5 Ruzicka et al, 1997; Boguniewicz et al, 1998; Hani¢n et al, 2001a (two trials); Paller et al, 2001
Ultraviolet light therapy 4 Krutmann et al, 1998; Der-Petrossian et al, 2000; Reynolds et al, 2001; Tzaneva et al, 2001
Antihistamines 4 Langeland et al, 1994; La Rosa et al, 1994;Veien et al, 1995; Patel et al, 1997
Doxepin 3 Drake et al, 1994; 1999; Berberian et al, 1999
Montelukast 3 Capella et al, 2001; Pei et al, 2001a; Yanase and David-Bajar, 2001
Ascomycins 2 Van Leent et al, 1998; Luger et al, 2001
Chinese herbal medicine 2 Latchman et al, 1996; Fung et al, 1999
Emollients 2 Hani¢n et al, 1998; Andersson et al, 1999
Interferon 2 Jang et al, 2000; Noh and Lee, 2001
Massage 2 Schachner et al, 1998; Anderson et al, 2000
Sodium cromoglycate 2 Kimata and Hiratsuka, 1994; Moore et al, 1998
Acid electrolytic water 1 Sasai-Takedatsu et al, 1997
Bioresonance 1 Schoni et al, 1997
Detergents 1 Andersen et al, 1998
Hamamelis distillate 1 Korting et al, 1995
Mycobacterium vaccae 1 Arkwright and David, 2001
Nitrazepam 1 Ebata et al, 1998
Platelet activating factor 1 Abeck et al, 1997
Psychologic measures 1 Ehlers et al, 1995
Pyridoxine 1 Mabin et al, 1995b
Thymopentin 1 Stiller et al, 1994
Wet wrap bandaging 1 Pei et al, 2001b
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Symptoms Of the 93 trials identi¢ed, 80 (86%) included an
assessment of patient symptoms (Table III), with up to seven
symptoms being assessed in each trial. The majority of trials
assessed only pruritus (36 trials), or pruritus and sleep
disturbance (34 trials). Other symptoms such as dryness or
scaling (eight trials) and pain (one trial) were rarely measured.
The gradings for each of these symptoms ranged from 03 to
014 where speci¢ed. In 44 of the 80 trials (55%) patients’
symptom scores were combined with physicians’ objective
clinical sign scores to give an overall composite severity score, as
part of the SCORAD index (13 trials), Costa’s Simple Scoring
System (¢ve trials), the EASI (one trial), the ADSI (one trial),
Rajka and Langeland’s scoring system (one trial) (Rajka and
Langeland, 1989), or in a variety of unnamed scoring systems (23
trials). Only 17 of these 44 trials also presented the symptom
scores separately.
Disease extent Of the 93 trials identi¢ed, 62 (67%) included an
assessment of disease extent, using one of 20 di¡erent methods of
estimating body surface area involvement (Table IV). Of these 62
trials, 40 incorporated the disease extent data into a composite
scoring system including other signs and/or symptoms, as part
of the SCORAD index (15 trials), Costa’s score (¢ve trials),
Rajka’s index (one trial), EASI (¢ve trials), ADASI (one trial),
DASI (one trial), or as part of an unnamed scoring system (12
trials). In only nine of these trials were disease extent data also
presented separately.
A further 13 trials estimated disease extent indirectly by
grading clinical signs at several body sites and summing the
scores for each site. Of these, four trials assessed signs at six
body sites using the SASSAD index or an earlier version of this
index (Van Joost et al, 1994; Tan et al, 1996; Zurbriggen et al, 1999;
Harper et al, 2000). The remaining trials used a variety of
unnamed scoring systems, assessing clinical signs in either four
(Munro et al, 1994; Sasai-Takedatsu et al, 1997), ¢ve (Stalder et al,
1994), six (Zonneveld et al, 1996), 12 (Moore et al, 1998), 15 (Kimata
and Hiratsuka, 1994; Hiratsuka et al, 1996), or 20 body sites (La
Rosa et al, 1994; 1995;Valsecchi et al, 1996).
Global measures of disease severity An overall global severity
assessment was performed at the end of the study by the
investigators in 34 trials (37%) and by the patients in 26 trials
(28%). Various scales were used although a four-point scale was
most commonly employed (18 trials).
Other outcome measures Topical steroid requirements were
recorded in 15 trials, and antihistamine use in four trials.
Quality of life was measured in only three trials (3%), all
published between 2000 and 2001, using either the Children’s
Dermatology Life Quality Index (CDLQI) (Harper et al, 2000),
a modi¢ed CDLQI (Pei et al, 2001a), a modi¢ed Dermatology
Life Quality Index (Czech et al, 2000), or the family impact
questionnaire (Harper et al, 2000). The e¡ect of atopic dermatitis
on daily living was measured using an unnamed scale in two
further trials (Soyland et al, 1994; Pei et al, 2001b). A measure of
atopic dermatitis related distress (Marburg Atopic Dermatitis
questionnaire), global disability ratings and anxiety and
depression scales were used in one trial investigating psychologic
approaches to relapse prevention (Ehlers et al, 1995). A series
of behavioral and anxiety scales were also used in a study
investigating the e¡ects of massage therapy in children
(Schachner et al, 1998).
Duration of assessment The duration of RCTs ranged from 7
d to 3 y, with a median trial duration of 6 wk. Only 12 trials
(13%) followed patients for longer than 6 mo (Galli et al, 1994;
Ehlers et al, 1995; Isolauri et al, 1995; 2000; Tan et al, 1996;
Friedmann and Tan, 1998; Harper et al, 2000; Ricci et al, 2000;
Gutgesell et al, 2001; Holm et al, 2001; Niggemann et al, 2001;
Tzaneva et al, 2001).
Changes over time When the 25 RCTs published over the 2 y
period 2000^1 were compared with trials published in the
preceding 6 y period 1994^9, there was evidence of a signi¢cant
increase in the use of published severity indices (58% vs 15%,
po0.05), with the SCORAD index (six trials), EASI (three
trials), and SASSAD index (two trials) being the most widely
used indices over the last 2 y. There was also a signi¢cant
increase in the use of disease extent measurements over the last 2
y (92% vs 57%, po0.05), but no statistically signi¢cant
di¡erences in the number of RCTs assessing patient symptoms
or global changes in disease severity.
DISCUSSION
The principles of evidence-based medicine are used increasingly
in dermatology to guide clinical practice and resource allocation.
The production of therapy guidelines, compendiums of evidence
(Charman and Williams, 2001), and systematic reviews (Hoare
et al, 2000) is dependent on comparison of data from many di¡er-
ent sources, and is hindered by wide variations in trial methodol-
ogy. The current state of outcome measures for atopic dermatitis
can only be described as a mess. There are almost as many scales
as there are trials, and most are unvalidated and synthesized de
novo for each trial. Signs and symptoms are frequently mixed up
together, and patient-centered outcome measures seem to be ne-
glected by an obsession to measure ‘‘objective signs’’, which, when
tested for validity and repeatability, are less objective than one
would like (Charman and Williams, 2000). The huge variation
in outcome measures for atopic dermatitis described in this paper
refers to just the last 8 y. This time period contains only a fraction
of the total number of atopic dermatitis RCTs identi¢ed in a re-
cent systematic review covering over 270 trials published be-
tween 1966 and 1999 (Hoare et al, 2000), suggesting that the true
variation in outcome methodology is likely to be substantially
higher. Although analysis of trials over the last 2 y of the review
has shown a move towards improved standardization, over 40%
of RCTs are still using either unpublished or modi¢ed scales.
Clinical signs A huge profusion of clinical signs have been
measured, re£ecting the di⁄culties in de¢ning which objective
features best re£ect disease severity. Di¡erent gradings have been
used to quantify the same clinical features, and no single sign has
been used consistently across all studies, making comparison
across trials almost impossible. The choice of clinical signs has
generally been based on the opinion of panels of experts
(European Task Force on Atopic Dermatitis, 1993), although an
alternative is to assess which signs best predict changes in
patient-assessed morbidity. The latter method has been used
recently as part of a wider study1 involving 200 patients with
atopic eczema, and showed that three clinical signs (erythema,
excoriations, edema/papulation) were the best predictors of
patient-assessed morbidity (in preparation), although others such
as licheni¢cation are likely to be helpful in long-term studies.The
clinical meaning of percentage changes in continuous objective
scales will always be di⁄cult to interpret, and need to be
interpreted in conjunction with other outcome measures, as in
practice it is the patient who is treated and not the signs of the
disease. Furthermore, clinical signs are assessed by physicians at
one point in time only, and even when assessed every week may
fail to capture the £uctuating nature of the disease, especially
given the short duration of most trials in this study. Another
serious problem is the risk of bias if investigators choose new
combinations of signs in order to amplify the e¡ects of a
speci¢c treatment. In the ¢eld of psychiatry it has already been
demonstrated that trials are more likely to report that a
treatment is superior to control when an unpublished index
is used to make the comparison. In one study of
1 Charman CR,Venn AJ,Williams HC. Patient based outcome measures
for atopic dermatitis. Br J Dermatol 143 (Suppl 57):34, 2000 (abstr.)
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nonpharmacologic trials, one-third of ‘‘gold standard’’ claims of
treatment superiority would not have been made if published
scales had been used (Marshall et al, 2000).
Which named scale to use? Of the named objective clinical
scales in this review, three scales have been most widely
employed and tested: SCORAD, EASI, and SASSAD. All have
shown evidence of criterion and construct validity against global
assessments of disease severity, patient-assessed pruritus, and other
variables such as topical steroid use. Some interobserver variation
has been demonstrated with all three indices, and is likely to be a
problem with all scoring systems involving visual assessment by
physicians. Each has advantages and disadvantages, making it
di⁄cult to recommend one index as superior, although the
SCORAD index has been most widely used in trials.
SCORAD comprises a measurement of six clinical signs at a
representative body site, combined with an assessment of disease
extent and visual analog scales of pruritus and sleep loss to give a
maximum possible score of 103. It has been suggested that disease
severity can be categorized as mild (o15), moderate (15^40), or
severe (440) according to the objective components of the
index (clinical signs and disease extent), with typical changes in
scores from 4550 to 2530 being demonstrated in recent
clinical trials (Van Der Meer et al, 1999; Capella et al, 2001; Holm
et al, 2001).The index has extensive published data on validity and
reliability, although licheni¢cation and body surface area
measurements in particular have shown signi¢cant interobserver
variation in some studies (Charman and Williams, 2000).
Although SCORAD is a composite score, the measurements of
disease extent, signs, and symptoms can easily be separated and
Table III. Symptoms of atopic dermatitis assessed in 80 RCTs from 1994 to 2001
Symptom Grading No. of
studies
References
Pruritus/itch 0^10 32 Drake et al, 1994; 1999; Langeland et al, 1994; Munro et al, 1994; Soyland et al, 1994;
Broberg and Faergemann, 1995; Ehlers et al, 1995; Isolauri et al, 1995; 2000; Mabin et al, 1995b;
Hederos and Berg, 1996; Majamaa and Isolauri, 1997; Andersen et al, 1998; Boguniewicz et al, 1998;
Ebata et al, 1998; Ewing et al, 1998; Berberian et al, 1999; Zurbriggen et al, 1999; Anderson et al, 2000;
Czech et al, 2000; Der-Petrossian et al, 2000; Harper et al, 2000; Ricci et al, 2000;
Capella et al, 2001; Gutgesell et al, 2001; Hani¢n et al, 2001a; Holm et al, 2001;
Lintu et al, 2001; Niggemann et al, 2001; Reynolds et al, 2001; Tzaneva et al, 2001
0^9 1 Hani¢n et al, 1998
0^7 3 Harper, 1995; Schoni et al, 1997; Noh and Lee, 2001
0^6 3 Soyland et al, 1994; Krutmann et al, 1998; Cato et al, 2001
0^5 1 Schoni et al, 1997
0^4 2 Koopmans et al, 1995; Traulsen, 1997
0^3 or 4-point scale 35 Biagi et al, 1994; Drake et al, 1994; 1999; Galli et al, 1994; Kimata and Hiratsuka, 1994;
La Rosa et al, 1994; 1995; Marchesi et al, 1994; Stiller et al, 1994;Van Joost et al, 1994;
Bleehen et al, 1995; Jorizzo et al, 1995; Korting et al, 1995; Mabin et al, 1995a; Veien et al, 1995;
Hiratsuka et al, 1996; Lebwohl, 1996; 1999; Poyner and Dass, 1996; Ramsay et al, 1996;
Reidhav and Svensson, 1996;Valsecchi et al, 1996; Zonneveld et al, 1996; Patel et al, 1997;
Ruzicka et al, 1997; Sasai-Takedatsu et al, 1997; Andersen et al, 1998; Boguniewicz et al, 1998;
Maloney et al, 1998; Schachner et al, 1998;Van Leent et al, 1998; Henz et al, 1999; Jang et al, 2000;
Luger et al, 2001; Paller et al, 2001
1^3 1 Gimenez-Arnau et al, 1997
NS 5 Stalder et al, 1994; Bleehen et al, 1995; Holland et al, 1995;Ventura et al, 1996; Breneman et al, 2000
Pruritus relief 0^10 3 Drake et al, 1994; 1999; Berberian et al, 1999
0^3 1 Drake et al, 1999
5-point scale 1 Drake et al, 1994
Sleep disturbance 0^10 19 Majamaa and Isolauri, 1997; Isolauri et al, 1995; 2000; Mabin et al, 1995b; Hederos and Berg, 1996; Isolauri, 2000;
Ewing et al, 1998; Zurbriggen et al, 1999; Anderson et al, 2000; Czech et al, 2000; Der-Petrossian et al, 2000;
Harper et al, 2000; Ricci et al, 2000; Capella et al, 2001; Gutgesell et al, 2001; Holm et al, 2001;
Lintu et al, 2001; Niggemann et al, 2001; Reynolds et al, 2001
0^7 3 Harper, 1995; Schoni et al, 1997; Noh and Lee, 2001
0^6 1 Krutmann et al, 1998
0^5 1 Schoni et al, 1997
0^3 10 Kimata and Hiratsuka, 1994;Van Joost et al, 1994; Mabin et al, 1995a; Hiratsuka et al, 1996;
Zonneveld et al, 1996; Patel et al, 1997; Ruzicka et al, 1997; Sasai-Takedatsu et al, 1997;
Henz et al, 1999; Jang et al, 2000
1^3 1 Ebata et al, 1998
NS 2 Stalder et al, 1994; Bleehen et al, 1995
Skin dryness 0^14 1 Andersson et al, 1999
0^10 2 Humphreys et al, 1994; Hederos and Berg, 1996
0^7 1 Soyland et al, 1994
NS 1 Stalder et al, 1994
Dryness/burning 0^10 1 Broberg and Faergemann, 1995
Scaling 0^10 2 Humphreys et al, 1994; Hederos and Berg, 1996
Redness 0^7 1 Soyland et al, 1994
0^10 2 Humphreys et al, 1994; Hederos and Berg, 1996
Redness/swelling 0^3 1 La Rosa et al, 1995
Crusting 0^10 1 Hederos and Berg, 1996
Smarting pain 0^3 1 Reidhav and Svensson, 1996
Fidgeting 0^10 1 Hederos and Berg, 1996
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presented as individual measurements if required. EASI is a more
recently developed index, being the second most widely used
named scale over the last 2 y. The EASI measures four of the
clinical signs used in SCORAD (maximum score 72) and has
shown reasonably good reliability, with induration/papulation
assessments showing the most interobserver variability (Hani¢n
et al, 2001b). The assessment of disease extent forms an
important integral part of the index that is di⁄cult to separate
out from the overall score. The EASI does not attempt to
include symptoms in the overall score and these should be
measured separately. The SASSAD index uses the same six signs
as the SCORAD index, with the substitution of cracking for
edema/papulation (maximum score 108) (Berth-Jones, 1996).
Clear de¢nitions are included in the index, and validity has
been demonstrated in several trials although reliability data
are limited to one small study (Charman et al, 2002). Other
scales such as Costa’s Simple Scoring System are more time
consuming to administer and have been less widely used over
the last 2 y.
Surface area of involved skin Disease extent measurements
varied widely among RCTs, re£ecting the technical di⁄culties
previously reported for estimating surface area involvement in
skin diseases (Tiling-Grosse and Rees, 1993; Charman et al, 1999).
Atopic dermatitis is characterized by indistinct disease margins,
and the poor reliability of body surface area estimates means
that such measurements need to be interpreted with caution. In
over 50% of the RCTs that measured disease extent, the
measurement was then incorporated into a composite score with
arbitrary and variable weighting given to disease extent, signs,
and symptoms. In such trials, translating how changes in the
¢nal score accurately and meaningfully re£ect disease severity
becomes extremely di⁄cult.
Symptoms and quality of life ascribed low importance
Although patients’ symptoms are subjective, it is ultimately
around the control of these symptoms that the treatment of
atopic dermatitis revolves. Although most trials included an
assessment of itching or sleep disturbance, patients were rarely
asked to rate other aspects of their disease such as soreness or
discomfort,1 and patient global severity ratings were used in less
than a third of trials. Furthermore, quality of life was assessed in
only three of 93 trials. As symptoms are self-rated by patients,
regular assessments using diary records can be used to capture
£uctuations in disease activity and potentially provide a more
accurate long-term picture of the e¡ects of therapy. The problem
of combining severity scores rated by patients with those rated by
physicians has previously been highlighted (Finlay, 1996) but
continues to be widely practised in trials using composite
scoring systems.
An appeal for standardization In the absence of a gold
standard measure of atopic eczema severity, opinion on which
aspects of the disease are most important will always vary
between physicians, and also between physicians and patients.
Although it is generally accepted that symptoms, signs, and
extent are important, with extent measurements being given
less weighting than signs of disease intensity (Hani¢n, 1989),
the concept of consensus on an ‘‘ideal’’ objective scale is
unrealistic. It is possible, however, to propose a conceptual
framework for choosing the domains that should be covered
when measuring atopic dermatitis severity in the clinical trial
setting (Table V). Instead of attempting to design yet further
scales let us concentrate on using the most widely validated
indices available to allow better comparison between studies,
resisting modi¢cations to the tested scale unless absolutely
essential. The presentation of parameters in composite indices
Table IV. Assessment methods used for measuring body surface area involvement in atopic dermatitis
in 62 RCTs from 1994 to 2001
Method used to assess disease extent No. of studies References
Scale of 0%^100% using rule of nines 27 Munro et al, 1994; Stiller et al, 1994; Broberg and Faergemann, 1995;
Isolauri et al, 1995; 2000; Tan et al, 1996; Zonneveld et al, 1996;
Gimenez-Arnau et al, 1997; Majamaa and Isolauri, 1997; Andersen et al, 1998;
Lever et al, 1998; Schachner et al, 1998;Wolkerstorfer et al, 1998;
Van Der Meer et al, 1999; Zurbriggen et al, 1999; Der-Petrossian et al, 2000;
Harper et al, 2000; Jang et al, 2000; Ricci et al, 2000; Capella et al, 2001;
Gutgesell et al, 2001; Holm et al, 2001; Lintu et al, 2001;
Niggemann et al, 2001; Pei et al, 2001a; 2001b; Tzaneva et al, 2001
Scale of 0%^100% using transparent shapes of 100^1000 cm2 1 Ruzicka et al, 1997
Scale of 0%^100% using body schema of 1044 squares 1 Ehlers et al, 1995
Scale of 0%^100% using series of area scales 1^300 cm2 1 Poyner and Dass, 1996
Scale of 0%^100% (method not speci¢ed ) 3 Hederos and Berg, 1996; Czech et al, 2000; Arkwright and David, 2001
Scale of 0^3 1 Biagi et al, 1994
Scale of 1^3 2 Veien et al, 1995; Gimenez-Arnau et al, 1997
Scale of 0^6 2 Soyland et al, 1994; Breneman et al, 2000
Scale of 0^10 1 Soyland et al, 1994
Color-coded drawing using grid of parallel lines 2 cm apart 1 Yanase and David-Bajar, 2001
4 body zones ^ % area assessed in each zone 1 Andersson et al, 1999
4 body zones ^ area assessed 0^6 in each zone 5 Boguniewicz et al, 1998; Hani¢n et al, 2001a; Luger et al, 2001;
Paller et al, 2001
5.5 body zones ^ area assessed 1^3 in each zone 1 Fung et al, 1999
6 body zones ^ area de¢ned in thirds in each zone 2 Van Joost et al, 1994; Reynolds et al, 2001
10 body zones ^ area assessed 0^3 in each zone 5 Harper, 1995; Schoni et al, 1997; Krutmann et al, 1998; Henz et al, 1999;
Noh and Lee, 2001
14 body zones ^ % area assessed in each zone 1 Ewing et al, 1998
16 body zones ^ area assessed 0^3 in each zone 1 Lever et al, 1998
20 body zones ^ area assessed 1^3 in each zone 1 Latchman et al, 1996
20 body zones ^ % area assessed in each zone 1 Humphreys et al, 1994
32 body zones ^ % area assessed in each zone 2 Mabin et al, 1995a; 1995b
Disease extent classi¢ed as localized, limited, or generalized 2 La Rosa et al, 1995; Ramsay et al, 1996
Assessment method not speci¢ed 3 Holland et al, 1995;Ventura et al, 1996; Friedmann and Tan, 1998
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such as SCORAD or EASI separately, in addition to a total score,
allows more meaningful interpretation (Hani¢n et al, 2001a;
Lintu et al, 2001; Paller et al, 2001). Patient symptom
measurements should include an assessment of pruritus, and may
include other symptoms such as sleep disturbance and soreness.
Symptoms can be recorded on a regular basis using daily or
weekly diary records in order to capture disease relapses and
remissions (Thomas et al, 2002), and data should be presented
separately from physicians’ clinical measurements. Simple global
objective scores can provide useful information as they avoid the
complexities of composite clinical scoring systems and may
provide a more pragmatic indicator of clinically meaningful
change to practising physicians and their patients (Luger et al,
2001; Paller et al, 2001). Finally, the assessment of the impact of
treatment on quality of life is of great importance in a nonlife-
threatening condition such as atopic dermatitis, and can be easily
measured using a validated scoring system such as the
Dermatology Life Quality Index or children’s equivalent (Finlay
and Khan, 1994; Lewis-Jones and Finlay, 1995). Relative to the
large amount of time and resources being poured into the ¢eld
of atopic dermatitis research, too little attention has been paid to
what we are actually measuring and basing our decision-making
on. Although some steps have been taken over recent years, a
more generalized move towards improved standardization of
outcome measures in future trials will lead to better utilization
of research ¢ndings and more accurate information on the
e¡ectiveness of therapy for patients with this chronic and
debilitating disease.
Dr. Charman received funding for this research as part of a Health Services Research
Training Fellowship from theTrent NHS Research and Development Group.
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